Zedoary and the Liver: A 2025 Human Trial and What Rodent Hepatoprotection Actually Shows
The main Curcuma zedoaria page states plainly that “the human evidence for taking zedoary rhizome for any condition is essentially absent.” Researching this page found one specific, real exception: a 2025 randomised controlled trial of zedoary for fatty liver disease — the only adequately designed human efficacy trial of the whole rhizome located anywhere in this four-page series. It deserves to be reported precisely, because the opening of the trial’s conclusion (“effective in managing NAFLD”) goes further than its objective data: the authors themselves limit zedoary’s advantage over vitamin E to subjective symptoms, and the objective liver measures did not differ between the groups. That distinction is the most instructive single finding in this set.
Table of Contents
- The Claim
- The 2025 Non-Alcoholic Fatty Liver Disease Trial, in Full
- Reading the Trial Honestly: Objective Versus Subjective
- The Classic Rodent Hepatoprotection Literature
- Vinegar-Processing, a Quality Marker, and a Species-Identity Wrinkle
- The Aristolochia Substitution Study
- Liver-Adjacent: Alcohol Metabolism and Drug-Metabolising Enzymes
- A Single Antifibrotic Cell Study
- Verdict and Evidence Tier
- What Is Not Known
- Practical Cautions
- Key Research Papers
- Connections
- Featured Videos
The Claim
Liver protection is not one of zedoary’s headline traditional claims in the way the digestive-bitter or blood-moving reputations are, but it appears consistently as a secondary theme across Chinese, Unani and Korean herbal medicine, usually bundled with the “breaks stasis, clears accumulation” framing already discussed on the main page. The modern research base turns out to be more substantial than that secondary billing would suggest — and it now includes a genuine, if modest and unreplicated, human trial.
The 2025 Non-Alcoholic Fatty Liver Disease Trial, in Full
Ashraf, Rather and Mehraj, working from a government Unani-medicine research institute in Srinagar, India, published a randomised, single-blind, active-comparator trial of Curcuma zedoaria for non-alcoholic fatty liver disease (NAFLD, now more often called metabolic dysfunction-associated steatotic liver disease (MASLD)) in the Arab Journal of Gastroenterology in early 2025. The design, stated precisely:
- 68 patients with grade 1 (mild) or grade 2 (moderate) non-alcoholic fatty liver disease, randomised to zedoary powder in capsule form, 500 mg twice daily, or vitamin E, 400 mg twice daily, for 60 days.
- Single-blind (not double-blind) and active-comparator (vitamin E, not placebo) — both design choices that matter for how much confidence the result can carry.
- 50 of 68 patients completed the study and were analysed “per protocol” — meaning the 18 who dropped out are not accounted for in the reported results, which is a further limitation on top of the small starting sample.
- Primary endpoints were subjective symptom scores: dull ache in the right upper abdomen, dyspepsia, anorexia (loss of appetite) and malaise, assessed at five time points over the 60 days.
- Secondary endpoints were the objective measures: ultrasound-graded fatty liver severity, liver span on ultrasound, a lipid panel, and standard liver-function blood tests.
Reading the Trial Honestly: Objective Versus Subjective
This is where the trial has to be read carefully rather than summarised from the first half of its conclusion sentence, because the objective and subjective results tell different stories.
What the objective, measurable endpoints showed: no significant difference between the zedoary group and the vitamin E group. Liver span on ultrasound improved significantly in both groups with no difference between them. Fatty liver grade improved significantly in both groups, again with no significant difference between them (reported chi-squared statistic p = 0.135, comfortably above the conventional 0.05 threshold for significance). There were no changes in liver function markers or lipid parameters in either group, though the authors note zedoary produced a slight reduction in triglycerides.
What the subjective, symptom-based endpoints showed: both groups improved on most measures, but zedoary performed better than vitamin E on some of them. In the zedoary group, the share of patients reporting no loss of appetite (anorexia) went from 72% to 100% (p = 0.016), while the vitamin E group’s improvement was not statistically significant (p = 0.102). Malaise resolved in 84% of the zedoary group versus 8% of the vitamin E group (p < 0.0001) — the single largest between-group difference in the entire trial. Dull right-upper-abdominal ache and dyspepsia improved in both groups, with zedoary showing “more favourable” or “slightly better” outcomes.
The trial’s own conclusion states, in full: “Curcuma zedoaria Rosc. is effective in managing NAFLD, showing better outcomes than vitamin E in subjective parameters like dyspepsia, malaise, anorexia, and dull ache in RHC.” The authors themselves limit the advantage over vitamin E to subjective symptom scores; the opening claim that zedoary “is effective in managing NAFLD” goes further than the objective data. On every objective, biologically verifiable measure — the actual fatty liver grade on imaging, liver span, liver enzymes, the lipid panel — zedoary performed no differently from vitamin E. Vitamin E is itself an active comparator: in the 2010 PIVENS trial in adults without diabetes, vitamin E improved nonalcoholic steatohepatitis on liver biopsy more often than placebo (43% vs 19%, P = 0.001) and reduced liver fat (steatosis) and inflammation, but did not improve scarring (fibrosis) (Sanyal 2010). Two comparator arms improving together on subjective malaise and appetite scores, with neither group's actual disease severity moving differently from the other, is also consistent with a general suggestion or placebo-adjacent response to any twice-daily intervention delivered inside a supportive clinical relationship — the single-blind design, with no inert placebo arm, cannot rule that out. This is not a criticism unique to zedoary; it is the ordinary limitation of a small, single-blind, active-comparator, per-protocol-only trial, and it applies exactly as much to the vitamin E arm.
What this genuinely establishes: a signal worth a properly powered, double-blind, placebo-controlled follow-up trial with intention-to-treat analysis and a longer duration — and, notably, no drug-related adverse events over 60 days at this dose, which is real and useful safety information regardless of how the efficacy question resolves. What it does not establish: that zedoary treats fatty liver disease. That claim would require the objective endpoints to move, and in this trial they did not move differently from vitamin E, an active comparator that in the PIVENS trial improved liver fat and inflammation on biopsy but not scarring.
The Classic Rodent Hepatoprotection Literature
Beneath the 2025 trial sits a older and more conventional preclinical literature, running back to the 1990s, using standard toxin-induced liver injury models:
- Matsuda and colleagues (1998) isolated from the aqueous acetone extract of the rhizome — nine principal sesquiterpenes (furanodiene, germacrone, curdione, neocurdione, curcumenol, isocurcumenol, aerugidiol, zedoarondiol and curcumenone), plus curcumin (a curcuminoid, not a sesquiterpene) — and found all of them protective against D-galactosamine/lipopolysaccharide-induced acute liver injury in mice, a well-established hepatotoxin model. Mechanistic work traced the effect partly to inhibition of D-galactosamine-induced hepatocyte cytotoxicity directly and partly to reduced nitric oxide production in macrophages, connecting this liver-protective finding to the same NO-suppression pathway discussed on the inflammation and arthritis page.
- Chen and colleagues (2022) tested zedoary essential oil in human L02 liver cells exposed to hydrogen peroxide or tert-butyl hydroperoxide — both oxidative-stress toxins — and found protection traceable to the PI3K/Akt/FoxO1 signalling pathway, restoring mitochondrial function and redox balance. This is a cell-culture study, not an animal model, despite testing an “acute liver injury” endpoint.
Vinegar-Processing, a Quality Marker, and a Species-Identity Wrinkle
Chinese medicine vinegar-processes e zhu before using it for liver conditions specifically — already noted on the main page as a real pharmacological modification, not mere tradition. Cui and colleagues (2019) investigated this directly: comparing crude and vinegar-processed Curcuma zedoaria in cell-based oxidative liver-injury assays (hydrogen peroxide and tert-butyl hydroperoxide again), they identified epicurzerenone as a quality marker specifically associated with the vinegar-processed material’s superior hepatoprotective activity, concluding vinegar-processed zedoary is “more suitable for the treatment of oxidative liver diseases” than the crude rhizome.
This paper is also worth reading for what it says about identity, applying the marker-compound caution the main page raises about Chinese Pharmacopoeia sourcing directly to this exact citation: its own introduction describes “Curcuma zedoaria” as “dry stenophora of Curcuma phaeocaulis Val., Curcuma kwangsiensis… or Curcuma wenyujin” — the same three-species Chinese Pharmacopoeia ambiguity documented on the main Curcuma zedoaria page. A marker compound establishes potency for whatever plant material was actually tested; it says nothing about which of (at least) four possible Curcuma species produced it. This study, and the wider Chinese vinegar-processing literature generally, therefore describe chemistry demonstrated on Chinese-pharmacopoeia “e zhu” material of uncertain single-species origin, not necessarily on Curcuma zedoaria Roscoe specifically — the identical caution the main page already applies to the β-elemene literature.
The Aristolochia Substitution Study
One study in this literature runs in an unusual and genuinely favourable direction, and it deserves its own explanation. Ansari and colleagues (2021), also working within Unani medicine, investigated a specific traditional-medicine concept called abadal-i-adwiya — drug substitution, where one medicinal plant is formally recognised as standing in for another. The plant being substituted for is Aristolochia rotunda, a member of a genus responsible for one of the best-documented cases of herb-induced organ damage in the medical literature: aristolochic acid nephropathy, the kidney failure and urothelial cancer syndrome linked to Aristolochia species in several countries. The substitute proposed by Unani tradition is Curcuma zedoaria.
The study tested this directly: inducing liver injury in Wistar rats with carbon tetrachloride (CCl4), then treating separate groups with silymarin (the standard milk-thistle-derived positive control), A. rotunda extract, or C. zedoaria extract (45.73 mg/kg). Both the Aristolochia and zedoary groups showed significantly decreased bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) compared with the untreated injury group, and microscopic examination of the liver tissue showed “significant recovery” in both treated groups. The authors’ conclusion is that zedoary may serve as a viable substitute for a plant with genuine, documented organ toxicity — a favourable finding worth stating plainly rather than folding into a generic hepatoprotection list, though the authors themselves are appropriately cautious, calling for further phytochemical and clinical corroboration before treating the substitution as settled.
Liver-Adjacent: Alcohol Metabolism and Drug-Metabolising Enzymes
Two further findings sit adjacent to hepatoprotection proper, rather than inside it, and are included because they bear directly on how zedoary interacts with the liver’s metabolic machinery rather than on liver injury itself.
- Kimura and colleagues (2013) tested zedoary extract and its active compound curcumenone against alcohol-induced “drunkenness” (a behavioural sedation endpoint) in mice. The extract, its hexane-soluble fraction and curcumenone prevented drunkenness and reduced the rise in blood alcohol after a dose of alcohol, and curcumenone (10 and 30 mg/kg) raised the activity of the liver enzyme alcohol dehydrogenase, which breaks alcohol down; the authors attribute the effect to this increased liver alcohol dehydrogenase activity. This is a pharmacokinetic/behavioural finding in mice, not a hepatoprotection finding as such: it does not show that zedoary protects the liver from alcohol’s effects, only that it changed how quickly alcohol was cleared.
- Rodseeda and colleagues (2022) tested Thai herbal extracts, including zedoary, for inhibition of cytochrome P450 3A — the liver enzyme most responsible for metabolising a very large share of prescription drugs — using three named chemotherapy drugs (gefitinib, lapatinib, sorafenib) as test substrates. In human liver microsomes (test-tube preparations of liver enzymes), zedoary extract strongly blocked the CYP3A-driven breakdown of lapatinib and sorafenib, with IC50 values (the concentration that halves enzyme activity) of 4.18 and 7.59 micrograms per millilitre. This is directly relevant to the drug-interaction caution already raised on the cancer page of this set: an isolated CYP3A-inhibition finding gives the theoretical “zedoary could alter chemotherapy drug levels” caution actual enzyme-level grounding, rather than leaving it as pure inference from “other Curcuma species do this.”
A Single Antifibrotic Cell Study
Kim and colleagues (2005) tested a Korean preparation of Zedoariae rhizoma against cultured human hepatic myofibroblast cells — the cell type responsible for laying down the scar tissue of liver fibrosis — and found growth-inhibitory activity. This is a single in-vitro study on one specific cell process (myofibroblast proliferation) rather than a whole-liver fibrosis model, and its weight is limited accordingly: a plausible early signal for an antifibrotic mechanism, not evidence that zedoary treats or prevents cirrhosis.
Verdict and Evidence Tier
- Tier: one small human trial with a mixed result, plus a real rodent and cell-culture hepatoprotection literature. This is the only one of the four benefit areas in this set with any human efficacy data at all.
- Verdict on the 2025 non-alcoholic fatty liver disease trial: neither clearly positive nor absent — a genuine fourth category this set has to name explicitly. It is not absent (a trial was run), not straightforwardly positive (the objective disease measures did not differ from the vitamin E comparator), and not old, weak and positive in the sense used elsewhere on this site for historical, hard-to-retrieve work (it is recent, retrievable and precisely reported). The honest label is small, single-blind, active-comparator, positive on subjective endpoints only, null on every objective one, unreplicated. Each qualifier is load-bearing; dropping any of them misstates the trial.
- Verdict on rodent/cell hepatoprotection: consistent and mechanistically grounded, across independent laboratories and toxin models (D-galactosamine/lipopolysaccharide (LPS), CCl4, oxidative stress), but entirely preclinical.
- Verdict on the Aristolochia-substitution finding: a genuine safety-differentiation result, not a hepatoprotection claim in the usual sense — it says zedoary is a plausible, less-toxic alternative to a plant with documented organ damage, which is worth knowing independent of whether zedoary treats anything on its own.
What Is Not Known
- No double-blind, placebo-controlled trial of zedoary for non-alcoholic fatty liver disease or any other liver condition exists — the 2025 trial is single-blind, with vitamin E as an active comparator rather than placebo.
- No intention-to-treat analysis of the 2025 trial exists; 18 of 68 randomised patients (26%) were excluded from the per-protocol result, and what happened to them is not reported.
- No replication of the 2025 trial by an independent centre.
- No dose-finding data in humans beyond the single 500 mg twice-daily dose tested.
- No data on zedoary in more severe liver disease (grade 3 non-alcoholic fatty liver disease, established fibrosis, cirrhosis, viral or alcohol-related hepatitis) — the trial enrolled only mild-to-moderate non-alcoholic fatty liver disease.
- No human data on the cytochrome P450 3A inhibition: it was measured in test tubes (human liver microsomes), not in people, so there is no way to predict the size of a real drug interaction at any dose a person would actually consume.
Practical Cautions
The 2025 trial does not establish zedoary as a treatment for diagnosed fatty liver disease or any other liver condition, and it did not test zedoary as a replacement for standard care — weight management, addressing metabolic risk factors, and physician-directed monitoring; it was a single 60-day, single-blind, 50-patient trial with no difference from vitamin E on any objective measure. The main Curcuma zedoaria page’s existing cautions about gallstones and biliary obstruction apply here without modification: Curcuma species stimulate bile flow, which is not a benefit where a duct is obstructed. The cytochrome P450 3A4-inhibition finding above adds a specific, mechanistically grounded reason — not just a generic “herbs can interact with drugs” caution — why zedoary use matters for anyone taking a medication metabolised by that enzyme, which includes a very large fraction of commonly prescribed drugs.
Key Research Papers
- Ashraf A, Rather SA, Mehraj M. Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver disease: a randomized, single blind, controlled trial. Arab Journal of Gastroenterology. 2025;26(1):112–119. PubMed PMID: 39880723 — The human trial discussed in full above.
- Matsuda H, Ninomiya K, Morikawa T, Yoshikawa M. Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on D-galactosamine/lipopolysaccharide-induced liver injury. Bioorganic & Medicinal Chemistry Letters. 1998;8(4):339–344. PubMed PMID: 9871681 — The classic mouse hepatoprotection study, nine sesquiterpenes plus curcumin tested.
- Ansari AP, Sana SH, Dar MY, Goswami P, Ahmed NZ. Validation of Unani concept of Abadal-i-Adwiya (drug substitution) by physicochemical standardization and hepatoprotective activity of Aristolochia rotunda Linn. and its substitute Curcuma Zedoaria Rosc. in albino Wistar rats. Journal of Complementary and Integrative Medicine. 2022;19(4):913–920 (online 2021). PubMed PMID: 34265879 — The Aristolochia-substitution finding.
- Chen K, Li G, Cui H, et al. Systems pharmacology and GC-MS metabolomics reveal the efficacy and mechanisms of zedoary oil on acute liver injury induced by oxidative stress. Phytomedicine. 2022;104:154295. PubMed PMID: 35802998 — In-vitro L02 hepatocyte protection.
- Cui H, Zhang B, Li G, et al. Identification of a quality marker of vinegar-processed Curcuma zedoaria on oxidative liver injury. Molecules. 2019;24(11):2073. PubMed PMID: 31151312 — Also the source of the species-identity caution above.
- Kim DI, Lee TK, Jang TH, Kim CH. The inhibitory effect of a Korean herbal medicine, Zedoariae rhizoma, on growth of cultured human hepatic myofibroblast cells. Life Sciences. 2005;77(8):890–906. PubMed PMID: 15964308
- Ayati Z, Ramezani M, Amiri MS, et al. Ethnobotany, phytochemistry and traditional uses of Curcuma spp. and pharmacological profile of two important species (C. longa and C. zedoaria): a review. Current Pharmaceutical Design. 2019;25(8):871–935. PubMed PMID: 30947655
- Rodseeda C, Yamanont P, Pinthong D, Korprasertthaworn P. Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated the metabolism of gefitinib, lapatinib and sorafenib. Toxicology Reports. 2022;9:1846–1852. PubMed PMID: 36518483 — The CYP3A4 drug-interaction grounding.
- Kimura Y, Sumiyoshi M, Tamaki T. Effects of the extracts and an active compound curcumenone isolated from Curcuma zedoaria rhizomes on alcohol-induced drunkenness in mice. Fitoterapia. 2013;84:163–169. PubMed PMID: 23160092
- Lobo R, Prabhu KS, Shirwaikar A, Shirwaikar A. Curcuma zedoaria Rosc. (white turmeric): a review of its chemical, pharmacological and ethnomedicinal properties. Journal of Pharmacy and Pharmacology. 2009;61(1):13–21. PubMed PMID: 19126292
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;362(18):1675–1685. PubMed PMID: 20427778 — The PIVENS trial; vitamin E’s effect on liver biopsy.
Connections
- All Herbs
- Zedoary (Curcuma zedoaria) — the main article, including the Chinese Pharmacopoeia species-identity chaos this page’s vinegar-processing section relies on.
- Zedoary Benefits Deep Dive — the hub.
- Zedoary for Inflammation and Arthritis — the same NO/macrophage mechanism underlying part of the hepatoprotection literature.
- Zedoary and Cancer — the drug-resistance-reversal mechanism that makes the cytochrome P450 3A4 (CYP3A4) finding on this page matter for chemotherapy patients specifically.
- Zedoary for Wound Healing and Topical Use.
- Milk Thistle — the herb whose extract, silymarin, served as the positive control in the Aristolochia-substitution study.
- Metabolic Dysfunction-Associated Steatotic Liver Disease / Non-Alcoholic Fatty Liver Disease — the condition the 2025 trial addressed.
- Gallstones — the condition behind the bile-flow-stimulation caution.
- Vitamin E — the active comparator in the 2025 trial.